Praluent (alirocumab)
|
|
- Alvin Cameron
- 5 years ago
- Views:
Transcription
1 Praluent (alirocumab) Policy Number: Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Praluent when it is determined to be medically necessary because the criteria listed below are met. When Policy Topic is covered Food and Drug Administration (FDA)-Approved Indications 1. Heterozygous Familial Hypercholesterolemia [HeFH]. * Approve Praluent for 12 months if the patient meets the following criteria (A, B, C, D and E): A) The patient is aged 18 years; AND B) The patient has an LDL-C level 160 mg/dl (after treatment with antihyperlipidemic agents but prior to PCSK9 inhibitor therapy such as Praluent or Repatha) [documentation required]; AND C) The patient meets one of the following criteria (i or ii): i. The patient has tried at least 2 statins with at least one being a high-intensity statin therapy (i.e., atorvastatin 40 mg daily; Crestor 20 mg daily [as a single-entity or as a combination product]) * AND Zetia (ezetimibe tablets) [as a single-entity or as a combination product] concomitantly for 8 continuous weeks [documentation required]; AND the LDL-C level remains 70 mg/dl [documentation required]; OR ii. The patient has been determined to be statin intolerant by meeting one of the following criteria (a or b): a) The patient experienced statin-related rhabdomyolysis (statin-induced muscle breakdown with signs and symptoms such as muscle pain, weakness, tenderness, acute renal failure and/or elevated creatine kinase [CK] levels [e.g., 10 times the upper limit of normal]) [documentation required]; OR b) The patient experienced skeletal-related muscle symptoms (e.g., myopathy [muscle weakness] or myalgia [muscle aches, soreness, stiffness, or tenderness]) and meets both of the following criteria [(1) and (2)]: (1) The skeletal-related muscle symptoms (e.g., myopathy or myalgia) occurred while receiving separate trials of both atorvastatin and Crestor (as single-entity or as combination products) [documentation required]; AND (2) When receiving separate trials of both atorvastatin and Crestor (as singleentity or as combination products) the skeletal-related muscle symptoms (e.g., myopathy, myalgia) resolved upon discontinuation of each respective statin therapy (atorvastatin and Crestor); AND D) Praluent is prescribed by, or in consultation with, a cardiologist; an endocrinologist; or a physician who focuses in the treatment of cardiovascular (CV) risk management and/or lipid disorders; AND E) If able to tolerate statins, the patient continues to receive the maximum tolerated dose of a statin while receiving Praluent therapy.
2 2. Hyperlipidemia in Patients with Clinical Atherosclerotic Cardiovascular Disease (ASCVD). * Approve Praluent for 12 months if the patient meets the following criteria (A, B, C, D and E): A) The patient is aged 18 years; AND B) The patient meets the following criteria (i and ii): i. The patient has an LDL-C level 70 mg/dl (after treatment with antihyperlipidemic agents but prior to PCSK9 inhibitor therapy such as Praluent or Repatha) [documentation required]; AND ii. The patient has had one of the following conditions or diagnoses (a, b, c, d, or e): a) The patient has had a previous myocardial infarction (MI) or has a history of an acute coronary syndrome (ACS); OR b) The patient has a diagnosis of angina (stable or unstable); OR c) The patient has a past history of stroke or transient ischemic attack (TIA); OR d) The patient has peripheral arterial disease (PAD); OR e) The patient has undergone a coronary or other arterial revascularization procedure in the past; AND C) The patient meets one of the following criteria (i or ii): i. The patient has tried at least 2 statins with at least one being a high-intensity statin therapy (i.e., atorvastatin 40 mg daily; Crestor 20 mg daily [as a single-entity or as a combination product]) * AND Zetia (ezetimibe tablets) [as a single-entity or as a combination product] concomitantly for 8 continuous weeks [documentation required]; AND the LDL-C level remains 70 mg/dl [documentation required]; OR ii. The patient has been determined to be statin intolerant by meeting one of the following criteria (a or b): a) The patient experienced statin-related rhabdomyolysis (statin-induced muscle breakdown with signs and symptoms such as muscle pain, weakness, tenderness, acute renal failure and/or elevated creatine kinase [CK] levels [e.g., 10 times the upper limit of normal]) [documentation required]; OR b) The patient experienced skeletal-related muscle symptoms (e.g., myopathy [muscle weakness] or myalgia [muscle aches, soreness, stiffness, or tenderness]) and meets both of the following criteria [(1) and (2)]: (1) The skeletal-related muscle symptoms (e.g., myopathy or myalgia) occurred while receiving separate trials of both atorvastatin and Crestor (as single-entity or as combination products) [documentation required]; AND (2) When receiving separate trials of both atorvastatin and Crestor (as singleentity or as combination products) the skeletal-related muscle symptoms (e.g., myopathy, myalgia) resolved upon discontinuation of each respective statin therapy (atorvastatin and Crestor); AND D) Praluent is prescribed by, or in consultation with, a cardiologist; an endocrinologist; or a physician who focuses in the treatment of cardiovascular (CV) risk management and/or lipid disorders; AND E) If able to tolerate statins, the patient continues to receive the maximum tolerated dose of a statin while receiving Praluent therapy. * Note: The number of drug-drug interactions that are categorized as severe or as unmodifiable by using lower doses or alternating to another statins or medications to manage the condition are limited. Exceptions based on current use of these other medications are not intentionally provided for in this policy. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical ASCVD, who require additional LDL-C lowering. 1 In this criteria, ASCVD was defined according to that described in the 2013 ACC/AHA guidelines for the treatment of blood cholesterol. Statins are well-established therapies and should be utilized first-line in all eligible patients with elevated LDL-C levels for patients without contraindications for use who are able to tolerate these
3 agents. Data with statins, as well as Zetia added to a statin, have noted reductions in CV events. 9,18-21 At this time, CV outcomes data are not available with Praluent. Patients with ASCVD or HeFH are recommended to utilize maximally tolerated high-intensity therapy (atorvastatin 40 mg daily; Crestor 20 mg daily) first-line, along with Zetia, prior to Praluent therapy. The recently published IMPROVE-IT trial with Zetia demonstrated a reduction in CV events when Zetia was added to statin therapy (simvastatin) compared with simvastatin monotherapy in patients who had been recently hospitalized for an ACS event. As in the Praluent clinical trials and as recommended in the Praluent prescribing information, patients should continue to receive the maximally tolerated dose of statin to continue to receive the benefits established regarding CV event reduction. Use of Praluent should be judicious and under the guidance of a specialist physician (cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders) to assure other lipid lowering therapies have been maximized and to promote safe use of Praluent. The criteria also recognize situations in which patients are unable to take statin therapy (i.e., muscle related AEs) and that rechallenge with a different statin in such scenarios can lead to successful treatment with statin therapy. However, rhabdomyolysis, albeit rare, is a serious event and patients should not be rechallenged with statin therapy. The criteria were developed based on nationally-recognized guidelines regarding lipid management, clinical data for Praluent and other antihyperlipidemic therapies (e.g., statins, Zetia) as well as the professional opinion of specialized physicians. When Policy Topic is not covered Praluent has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for noncoverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.) 1. Concurrent use of Praluent with Juxtapid (lomitapide capsules) or Kynamro (mipomersen injection). Both of these agents are indicated as an adjunct to lipid-lowering medications and diet to modify lipid parameters (e.g., reduce LDL-C levels) in patients with homozygous familial hypercholesterolemia (HoFH) The efficacy and safety of using these medication regimens in combination with Praluent have not been established. 2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available. Considerations Prior authorization is recommended for prescription benefit coverage of Praluent. Although Praluent lowers LDL-C and could possibly be used in a variety of patients with hyperlipidemia, the most benefit with Praluent is noted among patients in conditions for which it is indicated (adults with HeFH or ASCVD). The intent of this policy is to recommend coverage in such patients who are likely to benefit from Praluent if LDL-C remains elevated after trial of other proven therapies (i.e., high-dose statins, Zetia). Because of the specialized skills required for evaluation and monitoring of this new therapy, approval requires Praluent to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for 12 months in duration. Documentation: For the Comprehensive Program, documentation will be required where noted in the criteria as [documentation required]. Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts and/or laboratory data. Description of Procedure or Service Praluent, a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C). 1 A limitation of use is that the effects of Praluent on cardiovascular (CV) morbidity and mortality has not been determined. The
4 recommended starting dose of Praluent is 75 mg administered subcutaneously (SC) once every 2 weeks (Q2W), since most patients achieve adequate LDL-C reduction with this dose. If the LDL-C response is inadequate, the Praluent dose may be increased to a maximum of 150 mg SC Q2W. It is recommended to assess LDL-C levels within 4 to 8 weeks of initiating or titrating Praluent to evaluate for response and adjust the dose, if needed. The most common adverse events (AEs) in patients treated with Praluent were nasopharyngitis (11.3%), injection site reactions (7.2%), and influenza (5.7%). AEs led to discontinuation of treatment in 5.3% of patients treated with Praluent. Rationale Clinical Data The efficacy of Praluent was assessed in several studies. 1 The Praluent prescribing information details five double-blind, placebo-controlled trials that enrolled 3,499 patients. In total, 36% of patients had HeFH and 54% of patients had clinical ASCVD (without familial hypercholesterolemia [FH]). Three of the five trials involved patients only with HeFH. Patients were receiving statin therapy at a maximally tolerated dose, with or without other lipid modifying therapies. All trials were at least 52 weeks in duration. The primary efficacy endpoint was the mean percent change in LDL-C from baseline which was assessed at Week 24. Three studies used an initial Praluent dose of 75 mg SC Q2W, followed by a potential dose increase to 150 mg SC Q2W at Week 12 for patients who did not achieve the predefined target LDL-C at Week 8. Two studies used only the Praluent 150 mg SC Q2W dose. 1 ODYSSEY LONG-TERM was a multicenter, double-blind, placebo-controlled trial that randomized patients to Praluent 150 mg SC Q2W (n = 1,553) or to placebo (n = 788). 1-2 The baseline LDL-C was 122 mg/dl. At Week 24, the treatment difference between Praluent and placebo in the mean LDL-C percent change was -58%. 1-2 ODYSSEY COMBO I study was a multicenter, double-blind, placebocontrolled trial that randomized patients to Praluent (n = 209) or placebo (n = 107). 1,3 The mean baseline LDL-C was 102 mg/dl. At Week 12, the mean percent change from baseline in LDL-C -45% with Praluent compared with 1% with placebo, and the treatment difference between Praluent 75 mg SC Q2W and placebo in the mean LDL-C percent change was -46%. 1,3 At Week 12, if additional LDL- C lowering was required based on pre-specified LDL-C criteria, the Praluent dose was increased to 150 mg SC Q2W for the remainder of the trial. At Week 24, the mean percent change from baseline in LDL-C was -44% with Praluent and -2% with placebo, and the treatment difference between Praluent and placebo in mean LDL-C percent change was -43% (P < ). The dose was increased to 150 mg SC Q2W in 17% of patients (n = 32/191) treated with Praluent for at least 12 weeks. 1 Two other multicenter, double-blind, placebo-controlled trials involved patients with HeFH who were randomized to receive Praluent (n = 490) or placebo (n = 245). The average LDL-C at baseline was 141 mg/dl. Considering both trials together, the Week 12 treatment difference between Praluent 75 mg SC Q2W and placebo in the mean LDL-C percent change was -48%. At Week 12, if additional LDL-C lowering was required, the Praluent dose was increased to 150 mg SC Q2W for the remainder of the trials. At Week 24, the mean treatment difference between Praluent and placebo in the mean LDL-C percent change from baseline was -54% (P < ). The Praluent dose was increased to 150 mg SC Q2W in 42% of patients (n = 196/469) treated with Praluent for at least 12 weeks. The LDL-C lowering effect was sustained during the trial. 1 ODYSSEY HIGH FH was a multicenter, double-blind, placebocontrolled trial that randomized patients with HeFH with a baseline LDL-C 160 mg/dl to receive Praluent 150 mg SC Q2W (n = 72) or placebo (n = 35). 1,4 The average LDL-C at baseline was 198 mg/dl. At Week 24, the mean percent change from baseline in LDL-C was -43% with Praluent and - 7% with placebo; the treatment difference between Praluent and placebo in the mean LDL-C percent change was -36% (P < ). Guidelines Praluent has not yet been addressed in clinical guidelines. Many guidelines are available regarding the treatment of patients with dyslipidemia. Two nationally recognized organizations (the American College of Cardiology [ACC]/American Heart Association [AHA] and the National Lipid Association [NLA]) have guidelines regarding the management of patients with elevated cholesterol and related conditions which are detailed below.
5 ACC/AHA Treatment of Blood Cholesterol to Reduce Atherosclerotic CV Risk in Adults In 2013, the ACC/AHA published guidelines on the treatment of blood cholesterol to reduce atherosclerotic CV risk in adults. 5 The guidelines state that many randomized controlled trials have demonstrated a consistent reduction in ASCVD events with use of statins in both primary and secondary prevention among populations most likely to benefit. The ACC/AHA guidelines identify four major groups who should be treated with an appropriate statin-intensive therapy. These groups include: 1) patients with clinical ASCVD, which includes patients with a past acute coronary syndrome (ACS), or history of a myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial disease (PAD) presumed to be atherosclerotic origin; 2) patients with primary elevations of LDL-C 190 mg/dl; 3) patients 40 to 75 years of age with diabetes and an LDL-C between 70 and 189 mg/dl (without ASCVD); and 4) patients without clinical ASCVD or diabetes with an LDL-C between 70 and 189 mg/dl, and have an estimated 10-year ASCVD risk 7.5%. The ACC/AHA guidelines emphasize the appropriate intensity of statin therapy to reduce CV risk in patients who will benefit. 5 No statin is preferred, but instead, statins with related doses are categorized as high-intensity (lowers LDL-C by approximately 50%), moderate-intensity (lowers LDL-C by approximately 30% to < 50%), and low-intensity (lowers LDL-C by < 30%). Only atorvastatin and Crestor (rosuvastatin tablets) are categorized as high-intensity statin therapy, which is recommended for many patient populations at high CV risk. Table 1 categorizes the different statin regimens as high-, moderate-, and low-intensity. Refer to the guideline for the most appropriate intensity for the individual patient. These guidelines do not focus on LDL-C goals but emphasize the benefits of LDL-C reduction. Evidence from randomized controlled trials demonstrates that ASCVD events are reduced when patients use the maximum tolerated statin intensity in the groups in which benefits have been demonstrated. Table 1. High-, Moderate-, and Low-Intensity Statin Therapy. 5* High-Intensity Statin Therapy Moderate-Intensity Statin Therapy Low-Intensity Statin Therapy Daily dose lowers LDL-C on average by approximately 50%. Daily dose lowers LDL-C on average by approximately 30% to < 50%. Daily dose lowers LDL-C on average by < 30%. Atorvastatin (40 mg ) to 80 mg Crestor 20 mg (40 mg) Atorvastatin 10 mg (20 mg) Crestor (5 mg) 10 mg Simvastatin 20 mg to 40 mg Pravastatin 40 mg (80 mg) Lovastatin 40 mg Lescol XL 80 mg Fluvastatin 40 mg BID Livalo 2 mg to 4 mg Simvastatin 10 mg Pravastatin 10 mg to 20 mg Lovastatin 20 mg Fluvastatin 20 mg to 40 mg Livalo 1 mg * Individual responses to statin therapy varied in the randomized controlled trials and should be expected to vary in clinical practice. There might be a biologic basis for a less-than-average response; Specific statins and doses are bolded that were evaluated in randomized controlled trials in which a major reduction in cardiovascular events was demonstrated. Statins and doses that are approved by the Food and Drug Administration but were not tested in randomized controlled trials are in italics; LDL- C Low-density lipoprotein cholesterol; Evidence from one randomized controlled trial only and down titration is recommended if the patient is unable to tolerate atorvastatin 80 mg; Although simvastatin 80 mg was assessed in randomized controlled trials, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the Food and Drug Administration due to the increased risk of myopathy, including rhabdomyolysis; BID Twice daily.
6 NLA Management of Dyslipidemia In 2014, the NLA published recommendations for patient-centered management of dyslipidemia. 6-7 The guidelines recommend treatment goals. Regarding LDL-C, patients at low, moderate, or high risk are recommended to obtain an LDL-C level < 100 mg/dl. Patients at very high risk are recommended to achieve an LDL-C level < 70 mg/dl. Patients with ASCVD are included among the patients defined as being very high risk. Patients at high risk include those with an LDL-C 190 mg/dl, which suggests that patients may have FH. Unless contraindicated, first-line drug therapy for the treatment of disorders involving dyslipidemia includes a moderate- or high-intensity statin. High-intensity statin therapy includes atorvastatin (40 to 80 mg once daily [QD]) or Crestor (20 to 40 mg QD), which leads to an LDL-C reduction of 50%. The guidelines also note that one risk indicator also includes patients with an LDL-C 160 mg/dl. NLA Familial Hypercholesterolemia In 2011, the NLA published guidelines for the screening, diagnosis, and management of pediatric and adult patients with FH. 8 FH encompass a group of genetic defects that cause severe elevations in LDL- C levels, as well as other lipid parameters. HeFH occurs in approximately 1 in 300 to 500 patients and is present in childhood. Total cholesterol (total-c) levels in HeFH range from 350 to 550 mg/dl, which can result in premature ASCVD. Aggressive lipid-lowering therapy is recommended to achieve LDL-C reductions of at least 50%. Both children and adults with LDL-C levels 190 mg/dl following lifestyle modifications will require medication therapy. Statins are the initial treatment for all adults with FH. Higher risk patients may require intensification of drug therapy to achieve the more aggressive treatment goals. Intensification of medication therapy should be considered if LDL-C remains 160 mg/dl or if an initial 50% reduction in LDL-C is not achieved. Other Lipid-Lowering Therapies The ACC/AHA guidelines note that there is substantially less evidence for non-statin medications in reducing ASCVD risk. 5 However, the guidelines became available prior to publication of the IMPROVE- IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) with Zetia (ezetimibe tablets). 9 The trial involved patients (n = 18,144) who had been hospitalized for an ACS within the last 10 days; the mean LDL-C at baseline was 93.8 mg/dl. Patients receiving standard therapy for the treatment of ACS were also randomized in a double-blind manner to receive Zetia 10 mg QD plus simvastatin 40 mg QD or simvastatin 40 mg QD. The median follow-up was 6 years. The median timeweighted average LDL-C level during the trial was 53.7 mg/dl in the Zetia plus simvastatin 40 mg group compared with 69.5 mg/dl in the simvastatin 40 mg monotherapy group (P < 0.001). The Kaplan-Meier event rate for the primary endpoint at 7 years (composite of CV death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization [ 30 days after randomization] or nonfatal stroke) was 32.7% with Zetia plus simvastatin 40 mg QD vs. 34.7% with simvastatin 40 mg QD (P = 0.016). 9 Of note, adding Zetia to statins leads to additional decreases of LDL-C by up to - 25% The NLA guidelines for the management of dyslipidemia recommend therapy with a statin plus additional agents for those who have not achieved treatment goals for atherogeneic cholesterol levels, especially patient at very high or high risk. 6-7 Statin-Associated Adverse Events (AEs) Statins have been associated with muscle-related AEs such as myalgia (e.g., muscle aches, soreness, stiffness, or tenderness), myopathy (muscle weakness), and/or myositis (muscle inflammation). 12 Although the incidence is variable, muscle AEs are reported in around 5% of patients receiving statins, but may be due to other causes (e.g., excessive exercise, other medical conditions [hypothyroidism], non-statin medications). Rhabdomyolysis, which is uncommon with statin therapy, is a severe musclerelated AE that results in muscle breakdown and may or may not be associated with muscle-related symptoms (e.g., muscle pain, weakness, tenderness) along with acute renal failure and/or elevated creatine kinase [CK] levels. In patients with statin-related muscle AEs, symptoms may not re-occur if the patient switches to a different statin therapy.
7 In 2014 the NLA Statin Intolerance Panel published an update. 13 It was stated that most statin intolerance is due to myalgia. The strongest evidence at present for statin intolerance in a population is that myalgia appears but then remits with withdrawal, but reoccurs with rechallenge. The incidence of statin intolerance is widely variable. The Panel states that statins are among the safest medications available. The Panel does advise that due to statin benefits, it is safe to recommend a patient continue statin therapy even when some degree of statin intolerance is present, if patient can reasonably tolerate the statin. 13 A pivotal trial with Praluent called ODYSSEY ALTERNATIVE defined statin intolerance as the inability to take at least two different statins due to muscle-related AE, of which one statin was administered at the lowest approved starting dose. 14 Data also suggest that many patients who are rechallenged with statin therapy after an AE may be able to tolerate statin therapy long-term Of note, in the ODYSSEY ALTERNATIVE trial with Praluent, 69.8% of patients who were considered statin intolerant were treated with atorvastatin 20 mg QD and completed the double-blind 24-week portion of the trial. 17 This suggests that rechallenge with a statin in those purported to be statin intolerant is reasonable and may lead to successful use of a statin therapy. References 1. Praluent injection for subcutaneous use [prescribing information]. Bridgewater, NJ and Tarrytown, NY: sanofi-aventis and Regeneron Pharmaceuticals; July Robinson JG, Farnier M, Krempf M, et al, for the ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16) Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO 1 study. Am Heart J. 2015;169; e Ginsberg HN, Rader DJ, Raal FJ, et al. ODYSSEY FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia [abstract]. Circulation. 2014;130(23): Stone NJ, Robinson J, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation. 2014;129(25 Suppl 2):S1-S45. Available at Accessed on July 23, Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patientcentered management of dyslipidemia: Part 1-executive summary. J Clin Lipidol. 2014;8: Available at: Accessed on July 23, Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patientcentered management of dyslipidemia: Part 1-full report. J Clin Lipidol. 2015;9: Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011;5:S1-S8. 9. Cannon CP, Blazing MA, Giugliano RP, et al, for the IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25): Zetia tablets [prescribing information]. Whitehouse Station, NJ: Merck; August Morrone D, Weintraub WS, both PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2): Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58-S Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8:S72-S Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:
8 15. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;158(7): Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic Experience. Am Heart J. 2013;166(3): Praluent (alirocumab injection). Food and Drug Administration Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. June 9, Briefing Document. BLA Available at: ogicandmetabolicdrugsadvisorycommittee/ucm pdf. Accessed on July 23, Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380: Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev Jan 31;1:CD Cholesterol Treatment Trialists (CCT) Collaborators, Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomized trials: a meta-analysis. Lancet. 2008;371(9607) Baigent C, Keech A, Kearney PM, et al, for the Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493): Kynamro solution for subcutaneous injection [prescribing information]. Cambridge, MA: Genzyme; March Juxtapid capsules [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals; August Billing Coding/Physician Documentation Information Praluent is a pharmacy benefit Additional Policy Key Words ; Repatha Policy Implementation/Update Information 07/2015 New policy titled Praluent (alirocumab) 07/2016 Annual review- no changes to policy statement 07/2017 Annual review- no changes to policy statement 06/2018 Annual review- no changes to policy statement State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.
Repatha (evolocumab) Policy Number: Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019
Repatha (evolocumab) Policy Number: 5.01.601 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Repatha
More informationDrug Therapy Guidelines
Drug Therapy Guidelines PCSK9 Inhibitors: Praluent TM, Repatha TM Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 10/9/15
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationJuxtapid (lomitapide)
Juxtapid (lomitapide) Policy Number: 5.01.599 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Juxtapid
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationClinical Policy: Alirocumab (Praluent) Reference Number: CP.CPA.268 Effective Date: Last Review Date: 11.17
Clinical Policy: (Praluent) Reference Number: CP.CPA.268 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationHigh ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationPCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION PCSK9 Inhibitors Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017
Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationDrug Class Prior Authorization Criteria PCSK9 Inhibitors
Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationPatient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationJuxtapid and Kynamro
DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationPatient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationPatient Action Sets. Allscripts Touchworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Action Sets in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationPatient List Inquiries
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient List Inquiries in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for
More informationClinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19
Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:
Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationSubject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17
Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject PCSK9 Inhibitors Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 9 References... 9 Effective Date... 01/15/2018
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationReports. NextGen ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information
ABOUT THIS GUIDE This Guide provides a high-level overview of in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT (alirocumab)
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Alirocumab (Praluent) Reference Number: CP.PHAR.124 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kynamro) Reference Number: CP.PHAR.284 Effective Date: 10.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Evolocumab (Repatha) Reference Number: CP.PHAR.123 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationRegistry Processor Reports
ABOUT THIS GUIDE This Guide provides a high-level overview of Registry Processor Reports in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationPROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab)
PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationProprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection
REPATHA (evolocumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationRegistry Reports. eclinicalworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION
ABOUT THIS GUIDE This Guide provides a high-level overview of Registry Reports in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationApproximately 34% of adults in the United States
RESEARCH Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia
More informationEvan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More information1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?
09/07/2016 Prior Authorization AETA BETTER HEALTH OF KETUCK (MEDICAID) PCSK9 Inhibitors (K88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationQUANTITY LIMIT TARGET DRUGS- RECOMMENDED LIMITS Brand (generic) GPI Multisource Code Quantity Limit
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Criteria- Through Preferred Agent(s) Program Summary This program applies to Commercial, Netresults
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationSECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA
PRIMARY PREVENTION OF CHD AND STROKE IN HIGH RISK PATIENTS Random non fasting test for total cholesterol, HDL cholesterol (TC:HDL ratio) and LFTs If cholesterol > 7.5 mmol/l or LDL C 5mmol/l exclude secondary
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationAlirocumab (Praluent): First in the New Class of PCSK9 Inhibitors
DrUG FOrECAST Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors Marina Manniello, PharmD Candidate; and Michele Pisano, PharmD, CGP INTRODUCTION Hyperlipidemia, also known as hypercholesterolemia,
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, d Double-blind, bli Placebo- Controlled Study Evan A. Stein 1, David Sullivan 2,
More informationClass Update PCSK9 Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClass Update PCSK9 Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAlirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia
Alirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Alirocumab (Praluent,
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationMedication Policy Manual Policy No: Topic: Date of Origin: Committee Approval Date: Next Review Date: Effective Date: IMPORTANT REMINDER Description
Medication Policy Manual Policy No: dru301 Topic: Kynamro, mipomersen Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationPCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy
PCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy http://parriscardio.theangelheartcenter.com/wp-content/uploads/2013/03/heart-disease-prevention.jpg Jennifer Jiang, PharmD PGY1 Pharmacy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caduet) Reference Number: CP.CPA.237 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationGuidelines on Lowering LDL-C Levels
Scientific Insights Into LDL-C, PCSK9, and CV Risks High circulating LDL-C levels are associated with increased risk for ASCVD 1,2 Statin drugs interfere with cholesterol production, lowering serum LDL-C
More information